Expression of LC3B and FIP200/Atg17 in brain metastases of breast cancer
Authors:
- 9 August 2018
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 140 (2) , 237-248
Abstract
Background Macroautophagy/autophagy is considered to play key roles in tumor cell evasion of therapy and establishment of metastases in breast cancer. High expression of LC3, a residual autophagy marker, in primary breast tumors has been associated with metastatic disease and poor outcome. FIP200/Atg17, a multi-functional pro-survival molecule required for autophagy, has been implicated in brain metastases in experimental models. However, expression of these proteins has not been examined in brain metastases from patients with breast cancer. Methods In this retrospective study, specimens from 44 patients with brain metastases of infiltrating ductal carcinoma of the breast (IDC), unpaired samples from 52 patients with primary IDC (primary-BC) and 16 matched-paired samples were analyzed for LC3 puncta, expression of FIP200/Atg17, and p62 staining. Results LC3-puncta+ tumor cells and FIP200/Atg17 expression were detected in greater than 90% of brain metastases but there were considerable intra- and inter-tumor differences in expression levels. High numbers of LC3-puncta+ tumor cells in brain metastases correlated with a significantly shorter survival time in triple-negative breast cancer. FIP200/Atg17 protein levels were significantly higher in metastases that subsequently recurred following therapy. The percentages of LC3 puncta+ tumor cells and FIP200/Atg17 protein expression levels, but not mRNA levels, were significantly higher in metastases than primary-BC. Meta-analysis of gene expression datasets revealed a significant correlation between higher FIP200(RB1CC1)/Atg17 mRNA levels in primary-BC tumors and shorter disease-free survival. Conclusions These results support assessments of precision medicine-guided targeting of autophagy in treatment of brain metastases in breast cancer patients.Keywords
Funding Information
- National Institutes of Health (R01-CA152883, R01-CA175120)
- Cleveland Clinic Foundation (RPC 2010-1070-R1)
- METavivor Foundation
This publication has 49 references indexed in Scilit:
- Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancerJournal of Neuro-Oncology, 2018
- External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experienceThe Breast, 2018
- CCPG1 Is a Non-canonical Autophagy Cargo Receptor Essential for ER-Phagy and Pancreatic ER ProteostasisDevelopmental Cell, 2018
- The mammalian ULK1 complex and autophagy initiationEssays in Biochemistry, 2017
- Pharmacological modulation of autophagy: therapeutic potential and persisting obstaclesNature Reviews Drug Discovery, 2017
- Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic AdenocarcinomaAnnals of Surgical Oncology, 2015
- Metastasis suppressors in breast cancers: mechanistic insights and clinical potentialJournal of Molecular Medicine, 2013
- Suppression of Autophagy by FIP200 Deletion Impairs DNA Damage Repair and Increases Cell Death upon Treatments with Anticancer AgentsMolecular Cancer Research, 2011
- Analyses of Resected Human Brain Metastases of Breast Cancer Reveal the Association between Up-Regulation of Hexokinase 2 and Poor PrognosisMolecular Cancer Research, 2009
- Mechanism of Cell Cycle Regulation by FIP200 in Human Breast Cancer CellsCancer Research, 2005